Find compound explainers, evidence reviews, comparisons, product-specific preparation guidance and practical research tools. Use the protocol directory to start with a vial.
Source-linked mechanism library · 71 topics
Mechanism explainedIGF-1 LR3 is an engineered IGF-1 analogue designed to bind IGF-binding proteins less strongly than native IGF-1. Its evidence base is chiefly structural, cell-culture and animal research…
Read the research
Mechanism explainedBPC-157 is a synthetic 15-amino-acid peptide promoted for tissue repair, but the strongest direct evidence remains in cell systems and rodent injury models. Small human reports exist, yet…
Read the research
Mechanism explainedEvidence-grounded Australian educational material distinguishing the registered tirzepatide medicine from unregulated products, with primary clinical-trial results, safety context, and…
Read the research
Mechanism explainedRetatrutide is a purpose-designed peptide that activates GIP, GLP-1 and glucagon receptors. Randomised phase 2 trials have reported substantial short-term improvements in body weight and…
Read the research
Mechanism explainedTrace the hormone from hypothalamus to oxytocin receptor, then see why proven obstetric uses cannot be stretched into a promise about bonding or mood.
Read the research
Mechanism explainedThree missing amino acids change an experimental protein interaction. Follow the receptor pathway without turning cell and rat results into a human muscle-growth claim.
Read the researchShowing 179 articles
Solution inspectionFour clear illustrations show wall-side transfer, gentle swirling, no shaking, and why visible particles must be resolved or quarantined before use and product-specific storage.
Solution inspectionA safety-first troubleshooting guide explaining precipitation, aggregation, contamination, stopper fragments and why a persistently abnormal solution must be quarantined rather than rescued.
Solution inspectionA product-specific guide to dilute acetic-acid solution, peptide solubility, and why the vial instructions or lot-specific certificate of analysis must come before generic advice.
A product-specific guide to checking the vial, diluent, concentration, solution appearance and storage evidence before interpreting research charts.
Why a vial's mg amount cannot determine a compatible diluent or volume, plus simple concentration arithmetic once the product instructions are confirmed.
BPC-157 has mainly preclinical evidence; explore what the literature establishes, what remains unknown and how to interpret a research-vial label.
A head-to-head research overview that separates experimental mechanisms from established clinical outcomes and explains why a named blend is not a treatment protocol.
A head-to-head comparison of tirzepatide (dual GIP/GLP-1 agonist) and semaglutide (GLP-1 agonist) — two of the most researched metabolic peptides in test subjects.
A practical checklist for checking temperature, light protection, expiry, appearance and discard instructions for an exact peptide formulation.
A safety-first answer to common injection questions: which products have licensed directions, why research vials are different, and what to ask a clinician.
A clear guide to calculating concentration and liquid volume without confusing U-100 markings with biological IU or choosing a diluent from a vial's mg content.
Understanding the difference between bacteriostatic water and sterile water is essential for safe peptide reconstitution. This guide explains when to use each.
The CJC-1295 and Ipamorelin combination is the most popular growth hormone secretagogue stack in research. This guide covers dosing, timing, and cycle length.
Different peptides require different cycle lengths for optimal results in test subjects. This guide covers recommended on/off periods for every major research peptide.
An evidence-aligned Tirzepatide guide explaining the four-week initiation phase, maintenance-dose selection, and why dose increases are not automatic.
Comparing the dual agonist tirzepatide with the triple agonist retatrutide — the next generation of incretin-based metabolic peptides under research in test subjects.
Comparing the established GLP-1 agonist semaglutide with the investigational triple agonist retatrutide — representing two different generations of metabolic peptide research.
Understanding the critical difference between CJC-1295 with DAC (sustained release) and without DAC (pulsatile release) — two variants of the same GHRH analog with very different pharmacokinetics.
Comparing the highly selective GH secretagogue ipamorelin with the broader-acting GHRP-6 — understanding their different side effect profiles and research applications in test subjects.
Comparing ipamorelin's high selectivity with GHRP-2's greater potency — two GH secretagogues with different trade-offs between clean release and maximum output in test subjects.
A direct comparison of GHRP-2 and GHRP-6 — two closely related growth hormone releasing peptides with distinct appetite and hormonal profiles in test subjects.
Comparing two Russian-developed nootropic peptides — Semax for cognitive enhancement through BDNF upregulation and Selank for anxiolytic effects through GABA modulation in test subjects.
Comparing sermorelin (the original GHRH analog) with CJC-1295 (the modified, more potent version) — understanding their pharmacokinetic differences for GH research in test subjects.
Comparing tesamorelin (researched specifically for visceral adipose reduction) with CJC-1295 (general-purpose GHRH analog) — two GHRH analogs with different research applications in test subjects.
